Apritant 150mg Injection
Rx RequiredSalt Composition: Fosaprepitant Dimeglumine
Expiry Date: 01/2028
Buy at $15.62
Inclusive of all taxes
1 Vial(s)
About The Product
Nausea and Vomiting
Description
Apritant 150mg Injection is a prescription based medication which is used to treat nausea and vomiting associated with cancer chemotherapy. It works by blocking the neurokinin -1 (NK1) receptor in the brain, thereby preventing the signals that trigger vomiting.
Medication active ingredient is Fosaprepitant Dimeglumine, a prodrug that quickly turns into aprepitant in the body, helping prevent nausea and vomiting. This injection should be administered under the supervision of a healthcare professional.
Indication
Treat nausea and vomiting in cancer patients
Common Side Effects
● Fatigue
● Diarrhea
● Indigestion
● Anemia
● Skin blistering, peeling
● Low white blood cell count
● Anemia
● Anaphylactic reactions
● Urinary tract infection
● Rash, urticaria
● Itching
● Abnormal physical weakness
● Infection
● Nerve damage
Dosage And Duration
- Apritant 150mg Injection is an oral administration, taken with or without food at the fixed time everyday.
- Do not stop taking this medication without consultation of a healthcare provider to ensure safety and effectiveness of the treatment.
- Doctor suggest to regular monitor the liver function test while taking this medication.
- In case you missed a dose then it is better to take it as soon as possible to increase the effectiveness of the medication.
Mechanism Of Action
In cancer patients, nausea and vomiting are common symptoms. It can lead to dehydration and poor nutrition.
Apritant 150mg Injection helps to reduce these symptoms by blocking neurokinin receptor which lowers both the symptoms nausea and vomiting. The medication is only used to cancer patients by improving patient comfort and enhances overall treatment outcomes.
Safety Advice
Faqs
Apritant 150mg Injection needed consistency, as it may take several day to show the result.
Do not skip or stop taking the medication without consulting a healthcare professional.
References
• Garnock-Jones, K. P.
(2016). Fosaprepitant dimeglumine: a review in the prevention of nausea and vomiting associated with chemotherapy.
Drugs, 76(14), 1365-1372. • Colon-Gonzalez, F., & Kraft, W. K.
(2010). Pharmacokinetic evaluation of fosaprepitant dimeglumine.
Expert opinion on drug metabolism & toxicology, 6(10), 1277-1286. • Van Belle, S. J., & Cocquyt, V.
(2008). Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.
Expert Opinion on Pharmacotherapy, 9(18), 3261-3270. • Candelario, N., & Lu, M. L.
R. (2016).
Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives. Cancer Management and Research, 77-82. • Cao, Z., Zhang, L., Huang, M., Xia, S., Sun, Y., Yu, X., ... & Xu, F.
(2025). Development and Validation of an HPLC Method for the Simultaneous Determination of Eight Related Substances in Fosaprepitant Dimeglumine API.
Chromatographia, 88(3), 205-214.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
